Pricing Log in Create free account

Relay Therapeutics, Inc. (RLAY) vs Telix Pharmaceuticals Limited (TLX)

Relay Therapeutics, Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Relay Therapeutics, Inc. and Telix Pharmaceuticals Limited are of similar size ($3.8B and $3.6B). Across the 8 metrics below, Relay Therapeutics, Inc. leads on 4 and Telix Pharmaceuticals Limited on 4.

Valuation

Metric RLAY TLX Biotechnology median
P/E n/m — 8.50
P/S 299.51 — 9.71
P/B 3.71 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 216.89 n/m 9.21
Earnings yield (9.64%) — (33.15%)
Free cash flow yield (6.44%) 0.00% (25.50%)

Profitability

Metric RLAY TLX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (2,815.49%) — 0.00%
Net margin (2,594.20%) — 0.00%
Free cash flow margin (1,924.59%) 0.00% 0.00%
Return on equity (36.77%) 0.00% (56.36%)
Return on assets (33.72%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RLAY TLX Biotechnology median
Revenue growth (TTM) (74.29%) — 6.02%
EPS growth (last fiscal year) 31.78% (120.00%) 30.26%
Revenue growth, 5-year CAGR (28.58%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric RLAY TLX Biotechnology median
Debt to equity 0.00 1.18 0.00
Current ratio 18.27 2.01 4.72
Net debt to EBITDA 1.84 6.25 0.96

Dividend

Metric RLAY TLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric RLAY TLX Biotechnology median
Market cap 3.79b 3.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack